Study links genetic variants to poor outcomes after anti-VEGF treatment for AMD
Patients underwent three monthly injections and as-needed injections for an additional 9 months; patients received an average of 6.4 injections.
The mean change in visual acuity at 12 months was a gain of 3.2 lines.
The AA genotype at the rs11200638 SNP on the HTRA1 promoter gene and GG genotype at rs10490924 (A69S) in LOC387715/ARMS2 correlated significantly with poor visual acuity outcome at 12 months after multiple correction (P = .001 and P = .002, respectively).
Patients with the AA genotype at the rs11200638 SNP on HTRA1 lost a mean 2.9 letters. Patients with the AG or GG genotypes at the same SNP gained a mean of 5.1 letters. The difference was statistically significant (P = .001).
Disclosure: The study authors have no relevant financial disclosures.